Vildagliptin + Metformin + sulfonylurea (SU) + Basal Insulin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM)
Conditions
Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Jun 1, 2013 → Feb 1, 2015
NCT ID
NCT01871558About Vildagliptin + Metformin + sulfonylurea (SU) + Basal Insulin
Vildagliptin + Metformin + sulfonylurea (SU) + Basal Insulin is a phase 3 stage product being developed by Novartis for Type 2 Diabetes Mellitus (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT01871558. Target conditions include Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01871558 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM)